The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic damage can be treated, along with the patients who have definitive ankylosing spondylitis. The result has been a billion-dollar market in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). A new wave of change is slated to come to the market, as drugs with new mechanisms of action are approved and as regulatory authorities clear the way for biologics to treat nr-AxSpA in the major markets
Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis (US)
The axial spondyloarthritis market is undergoing rapid change as physicians increasingly recognize both ankylosing spondylitis (AS) and non-radiographi...
Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis : Current Treatment: Physician Insights (EU5)
The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (
Axial Spondyloarthritis | Landscape & Forecast | Disease Landscape & Forecast
The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor alpha (
Axial Spondyloarthritis | Unmet Need | Detailed, Expanded Analysis (US & EU) : Non-radial axial spondyloarthritis : (US & EU5)
MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen&rsqu...